Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34(+) progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.

[1]  Anton Berns,et al.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.

[2]  J W Gray,et al.  Comprehensive genome sequence analysis of a breast cancer amplicon. , 2001, Genome research.

[3]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[4]  F. Bushman.  Targeting Survival Integration Site Selection by Retroviruses and LTR-Retrotransposons , 2003, Cell.

[5]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[6]  L. Cupples,et al.  A model for predicting the risk of cancer consequent to retroviral gene therapy. , 1992, Human gene therapy.

[7]  K. Harbers,et al.  Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions , 1990, Journal of virology.

[8]  F. V. von Eyben.  Chromosomes, genes, and development of testicular germ cell tumors. , 2004, Cancer genetics and cytogenetics.

[9]  Christine Kinnon,et al.  Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. , 2007, The Journal of clinical investigation.

[10]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[11]  M. Breindl,et al.  Transcriptionally active genome regions are preferred targets for retrovirus integration , 1990, Journal of virology.

[12]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[13]  C. von Kalle,et al.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.

[14]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[15]  Christof von Kalle,et al.  Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.

[16]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[17]  N. Copeland,et al.  Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. , 2005, Blood.

[18]  B. Aronow,et al.  Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.

[19]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. von Kalle,et al.  Polyclonal long-term repopulating stem cell clones in a primate model. , 2002, Blood.

[21]  Danielle Hulsman,et al.  Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice , 2002, Nature Genetics.

[22]  C. von Kalle,et al.  Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. , 2005, Blood.

[23]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[24]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[25]  Dick de Ridder,et al.  New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling , 2005, The Journal of experimental medicine.

[26]  Christine Kinnon,et al.  Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.

[27]  B. Fehse,et al.  Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.

[28]  High-throughput retroviral tagging to identify components of specific signalling pathways in cancer , 2002, Nature Reviews Cancer.

[29]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[30]  A. Jauch,et al.  Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. , 2003, Blood.

[31]  J. Coffin,et al.  Relationship between retroviral DNA-integration-site selection and host cell transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[33]  T. Rabbitts,et al.  The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.